With over 30 years of inhalation product experience, Catalent Inhalation can handle the most complex projects and help bring orally inhaled and nasal therapies to market faster. Whether a single service or a comprehensive development package is required, Catalent offers end-to-end expertise in dry powders for inhalation (DPI), as well as liquid and powder, unit-dose, bi-dose, and multi-dose nasal products.
Watch our video “Pathways for Pulmonary Delivery”
New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small molecules and systemic indications. Nebulizer and dry power inhaler modalities are growing and driving demand for specialized CDMOs like Catalent, who can provide the end-to-end solutions, scientific knowledge, and the scalable manufacturing capabilities necessary to meet the needs of inhalation innovators and accelerate time to market.
Learn more about Catalent’s services for OINDP development and manufacturing:
Article: ARCUS®: A Commercialized Technology Enabling High-Dose, Highly Respirable Powders
Spray drying to manufacture powders for inhalation is now a well-established practice in the pharmaceutical industry that allows for the production of highly respirable, high-dose formulations. ARCUS technology incorporates the benefits of spray drying with a capsule-based high-capacity device. As one of only three commercially approved technologies for spray drying inhalable powder, ARCUS provides an opportunity to design an inhalation product with an established and successful regulatory track record. This article discusses the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.
Article: Your Perfect Partner for Dry Powder Inhalation
There is growing interest and investment being made in dry powder inhalation technology and an increasing confidence in inhalable dry powders as a means of drug delivery. Spray drying offers significant advantages when it comes to powder production with key advantages to precisely control particle size, morphology and surface properties, as well as increase drug load, which is crucial for optimal drug delivery to the lungs and, potentially, to the nasal cavity with high nasal deposition efficiency. This article, originally published in Pharmaceutical Manufacturing and Packing Sourcer, discusses how to successfully develop and manufacture spray-dried pulmonary and nasal powders and how a CDMO partner plays an integral role in the successful development and commercialization of inhalation products.
Article: Spray Drying to Enable New Inhaled Drug Products
There are many key process inputs and variables that must be considered when designing an inhaled formulation and the associated spray-drying process. Originally published in Inhalation magazine, this article discusses ways in which scientists and engineers should consider the variables under their control and expands these considerations into current applications.
Article: Intranasal Drug Delivery – the Challenges and Opportunities
The intranasal delivery route is commonly used for the local treatment of allergic rhinitis and cold symptoms, but it is also recognized as an alternative systemic drug delivery route for a variety of indications, including migraine, seizures, breakthrough pain, and opioid overdose. In this article, originally published in Pharmaceutical Manufacturing and Packing Sourcer, experts discuss how the intranasal route offers advantages like faster absorption and minimal product degradation, but also the complex issues to consider when designing a device that will ensure the efficacy of a particular formulation.
Article: Unraveling the Complexities in Nasal Vaccine Development, Manufacturing, and Device Selection
This article discusses developing intranasal products and scaling them for commercial supply. The nasal delivery of vaccines is a growing field in terms of investment in research and development resources along with late-phase clinical trials. It is not a matter of “if” but “when” we will see the next nasal vaccine approved. Choosing a development and manufacturing partner with a global presence and expertise in intranasal delivery is essential for product development and commercialization.